ABOUT ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to identify Harmless dosing routine. Further participants might be enrolled for the recognized monotherapy dosign regimen. In Section B, participants will receive oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Section C, participants